Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSPA5 | P11021 | 3/20 | 0.38 |
| ▸ | PDE2A | O00408 | 2/20 | 0.34 |
| ▸ | ATG7 | O95352 | 1/20 | 0.32 |
| ▸ | DOT1L | Q8TEK3 | 2/20 | 0.31 |
| ▸ | NT5E | P21589 | 1/20 | 0.30 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.30 |
| ▸ | HTR1A | P08908 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL264531 | 0.90 | BCHE (0.34) | HSPA5PDE2ANT5EHTR1A | |
| SCHEMBL13843313 | 0.83 | ADORA2A (0.37) | HSPA5ATG7 | |
| SCHEMBL13847083 | 0.83 | ADORA2A (0.37) | HSPA5ATG7 | |
| SCHEMBL264654 | 0.83 | TACR2 (0.32) | NT5EHTR1A | |
| SCHEMBL12261148 | 0.80 | HSPA5 (0.40) | HSPA5PDE2AATG7DOT1LTAAR1 | |
| SCHEMBL3363398 | 0.78 | NT5E (0.32) | NT5ETAAR1HTR1A | |
| SCHEMBL261244 | 0.78 | NT5E (0.32) | NT5ETAAR1HTR1A | |
| SCHEMBL260539 | 0.78 | NT5E (0.32) | NT5EHTR1A | |
| SCHEMBL260030 | 0.77 | NT5E (0.35) | NT5E | |
| SCHEMBL12365501 | 0.76 | HSPA5 (0.37) | HSPA5PDE2AATG7DOT1LTAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8344132-B2 | Methods for the preparation of 9-deazapurine derivatives | BioCryst Pharmaceticals, Inc. (US) | 2013-01-01 | — | — | US | disclosed |
| US-8344132-B2 | Methods for the preparation of 9-deazapurine derivatives | BioCryst Pharmaceticals, Inc. (US) | 2013-01-01 | — | — | US | disclosed |
| US-20100093991-A1 | METHODS FOR THE PREPARATION OF 9-DEAZAPURINE DERIVATIVES | BIO CRYST PHARMACEUTICALS , INC. (US) | 2010-04-15 | — | — | US | disclosed |
| US-20100093991-A1 | METHODS FOR THE PREPARATION OF 9-DEAZAPURINE DERIVATIVES | BIO CRYST PHARMACEUTICALS , INC. (US) | 2010-04-15 | — | — | US | disclosed |
| EP-1893625-A2 | METHODS FOR THE PREPARATION OF 9-DEAZAPURINE DERIVATIVES | Biocryst Pharmaceuticals, Inc. (US) | 2008-03-05 | — | — | EP | disclosed |
| WO-2007002191-A2 | METHODS FOR THE PREPARATION OF 9-DEAZAPURINE DERIVATIVES | BIOCRYST PHARMACEUTICALS, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093991-A1 | METHODS FOR THE PREPARATION OF 9-DEAZAPURINE DERIVATIVES | DPYD, TYMP, UNG | HSPA5 2687/4885PDE2A 1844/4885ATG7 2160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.